Optimising evidence generation in trial design, while navigating regulatory and local payer requirem...
Read moreNegotiations between the Trump administration and pharmaceutical companies on lowering U.S...
Read moreSuccessfully navigating early payer scientific advice whether through Joint Scientific Consultations...
Read moreProving the long-term value of pharmaceutical assets remains one of the biggest challenges for manuf...
Read moreWhether you’re in drug development, market access, or health economics, early scientific advic...
Read moreCharlie Hewitt from Remap Consulting initiated today’s session by providing a description of the c...
Read moreBack in January this year, we summarised the key trends our market access experts believed would dom...
Read moreOur market access experts provide an overview of how to get payer scientific advice between Septembe...
Read morePayer value proposition development and understanding evidence requirements to secure pricing and re...
Read moreAlmost a decade after it's inception, what have we learned from the UK early access to medicines sch...
Read more